These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 1591383)
1. Therapeutic implications of antisense oligonucleotides. Lattuada D; Mazzei M; Meazza R; Nicolin A Int J Clin Lab Res; 1992; 21(4):296-9. PubMed ID: 1591383 [TBL] [Abstract][Full Text] [Related]
2. Antisense strategies: functions and applications in immunology. Varga LV; Tóth S; Novák I; Falus A Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355 [TBL] [Abstract][Full Text] [Related]
3. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine. Oberbauer R Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943 [TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides: the state of the art. Aboul-Fadl T Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780 [TBL] [Abstract][Full Text] [Related]
5. Clinical trials of a new class of therapeutic agents: antisense oligonucleotides. Galderisi U; Cipollaro M; Cascino A Expert Opin Emerg Drugs; 2001 Apr; 6(1):69-79. PubMed ID: 15989497 [TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides for cancer therapy-an overview. Stahel RA; Zangemeister-Wittke U Lung Cancer; 2003 Aug; 41 Suppl 1():S81-8. PubMed ID: 12867066 [TBL] [Abstract][Full Text] [Related]
8. Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design. Delihas N; Rokita SE; Zheng P Nat Biotechnol; 1997 Aug; 15(8):751-3. PubMed ID: 9255788 [TBL] [Abstract][Full Text] [Related]
9. Antisense and/or immunostimulatory oligonucleotide therapeutics. Agrawal S; Kandimalla ER Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879 [TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT; Parkinson DR Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689 [TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides. Herdewijn P Verh K Acad Geneeskd Belg; 1996; 58(4):359-81. PubMed ID: 8956554 [TBL] [Abstract][Full Text] [Related]
12. Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Fisker N; Westergaard M; Hansen HF; Hansen JB Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1427-30. PubMed ID: 18066798 [TBL] [Abstract][Full Text] [Related]
13. [The application of antisense technology in ophthalmology]. Guo Y; Ge J Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046 [TBL] [Abstract][Full Text] [Related]
14. Towards genomic drug therapy with antisense oligonucleotides. Lönnberg H; Vuorio E Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110 [TBL] [Abstract][Full Text] [Related]
15. Antisense technology for cancer therapy: does it make sense? Carter G; Lemoine NR Br J Cancer; 1993 May; 67(5):869-76. PubMed ID: 8494718 [No Abstract] [Full Text] [Related]
16. Single strand targeted triplex-formation. Destabilization of guanine quadruplex structures by foldback triplex-forming oligonucleotides. Kandimalla ER; Agrawal S Nucleic Acids Res; 1995 Mar; 23(6):1068-74. PubMed ID: 7537368 [TBL] [Abstract][Full Text] [Related]
17. Thermodynamics of RNA-RNA duplexes with 2- or 4-thiouridines: implications for antisense design and targeting a group I intron. Testa SM; Disney MD; Turner DH; Kierzek R Biochemistry; 1999 Dec; 38(50):16655-62. PubMed ID: 10600128 [TBL] [Abstract][Full Text] [Related]
18. RNAi: a novel antisense technology and its therapeutic potential. Dallas A; Vlassov AV Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063 [TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of antisense oligonucleotides. Sharma HW; Narayanan R Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067 [TBL] [Abstract][Full Text] [Related]